

DETAILED ACTION

The amendment filed on April 01, 2008 has been acknowledged. Claim 1 has been amended. Claims 2, 10 and 14-28 were canceled. Claims 1, 3-9, 11-13, 29-30 are pending and considered.

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tamsen L. Barrett on June 30, 2008.

The application has been amended as follows:

Claim 1 (current amended). In line 1 after "response" please insert --- to an antigen --- In line 2 after "comprising" please delete "a peptide" and insert --- an isolated peptide consisting of an amino acid sequence, wherein the amino acid sequence is --- In line 4 after "comprising" please insert --- a heterologous ---

Claim 4 (current amended). In line 1 before "antigen", please delete "antigen comprises" and insert --- the heterologous antigen is ---

Claim 9 (current amended). In line 1 after "an immune response" and insert -- to an antigen ---

Claim 12(current amended). In line 1 before "antigen", please delete "antigen comprises" and insert --- the heterologous antigen is ---

Claims 1, 3-9, 11-13 and 29-30 are allowed.

2. The following is an examiner's statement of reasons for allowance: The amendment effectively overcomes all outstanding rejections made in the previous office action. No prior art teaches or suggests a composition comprising a particular peptide fused with another

Art Unit: 1648

heterologous antigen, wherein the peptide consists of an amino acid sequence selected from group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7, and the heterologous antigen is preferably cholera toxin. The fusion protein comprising such unique fusion protein that comprises a particular novel antigenic fusion protein with an amino acid sequence set forth in SEQ ID NO: 39.

3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 6:30 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bao Qun Li/
Examiner, Art Unit 1648

/Bruce Campell/
Supervisory Patent Examiner, Art Unit 1648

Application Number**Application/Control No.**

10/506,796

Examiner

Bao Qun Li

**Applicant(s)/Patent under
Reexamination**

MOR ET AL.

Art Unit

1648